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Application of two versions of the WHO/international society of hypertension
absolute cardiovascular risk assessment tools in a rural Bangladeshi population
Abstract
Objectives: To estimate the absolute cardiovascular disease (CVD) risk burden in a remote rural
Bangladeshi population using the 'With' and 'Without' Cholesterol versions of the WHO/International
Society of Hypertension (WHO/ISH) CVD risk assessment chart (particularly suitable for low and middleincome countries due to less reliance on laboratory testing) and to evaluate the agreement between the
two approaches. Design: Cross-sectional study using data from a large prospective cohort of the North
Bengal Non-Communicable Disease Programme (NB-NCDP) of Bangladesh. Setting: General rural
population from Thakurgaon district of Bangladesh. Participants: 563 individuals who were categorised
as having 'no CVDs' on screening by a questionnairebased survey using the 'WHO CVD-Risk Management
Package' developed in 2002. Main outcome measures: Absolute CVD risk burden assessed using two
versions of the WHO/ISH risk assessment charts for the South-East Asian Region-D. Results: 10-year risk
(moderate, high and very high) positivity was present among 21.5% and 20.2% of participants,
respectively, using with and without cholesterol versions of the tool. The overall concordance rate for the
two versions was 89.5% and they did not differ significantly in estimating the proportion of overall
participants having higher levels of CVD. The projected drug requirement, however, showed a significant
overestimation in the proportion of participants at both the threshold levels (p0.002) on using 'without' as
compared to 'with' cholesterol versions. Conclusions: About one-fifth of the adult population in
Bangladesh, even in a remote rural area, seem to be at risk of developing CVDs (25% of them at high risk
and 25% at very high risk) within 10 years with males and females being almost equally vulnerable.
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ABSTRACT
Objectives: To estimate the absolute cardiovascular
disease (CVD) risk burden in a remote rural
Bangladeshi population using the ‘With’ and ‘Without’
Cholesterol versions of the WHO/International Society
of Hypertension (WHO/ISH) CVD risk assessment chart
( particularly suitable for low and middle-income
countries due to less reliance on laboratory testing)
and to evaluate the agreement between the two
approaches.
Design: Cross-sectional study using data from a large
prospective cohort of the North Bengal NonCommunicable Disease Programme (NB-NCDP) of
Bangladesh.
Setting: General rural population from Thakurgaon
district of Bangladesh.
Participants: 563 individuals who were categorised
as having ‘no CVDs’ on screening by a questionnairebased survey using the ‘WHO CVD-Risk Management
Package’ developed in 2002.
Main outcome measures: Absolute CVD risk
burden assessed using two versions of the WHO/ISH
risk assessment charts for the South-East Asian
Region-D.
Results: 10-year risk (moderate, high and very high)
positivity was present among 21.5% and 20.2% of
participants, respectively, using with and without
cholesterol versions of the tool. The overall
concordance rate for the two versions was 89.5% and
they did not differ significantly in estimating the
proportion of overall participants having higher levels
of CVD. The projected drug requirement, however,
showed a significant overestimation in the proportion
of participants at both the threshold levels ( p<0.002)
on using ‘without’ as compared to ‘with’ cholesterol
versions.
Conclusions: About one-fifth of the adult population
in Bangladesh, even in a remote rural area, seem to
be at risk of developing CVDs (25% of them at
high risk and 25% at very high risk) within 10 years
with males and females being almost equally
vulnerable.

Strengths and limitations of this study
▪ Community-based study in a remote location on
a relatively traditional rural population; the
second reported work on absolute cardiovascular
disease (CVD) risk assessment on any
Bangladeshi population.
▪ Both without and with cholesterol versions of
the WHO/International Society of Hypertension
tool were used in parallel, for the first time in a
CVD-related study on a Bangladeshi population;
generates baseline data for future communitybased cohort studies.
▪ The sample size is relatively small, limiting
detailed analysis among various subgroups; the
cross-sectional nature of the study does not
allow inferences to be drawn on trends and
causality.
▪ Comparison with other absolute risk assessment
tools (like Framingham scoring) was not carried
out.

INTRODUCTION
Cardiovascular diseases (CVDs) are now the
major cause of death all over the world. It is
estimated by the WHO that 17.5 million
(31% of all death) people died from CVDs
in 2012.1 Of all deaths, about 80% occurred
in low-income and middle-income countries
(LMICs).2 Accurate estimation of CVD risk is
vital for both prevention and management of
CVDs as well as for designing long-term policies and programmes to combat the challenges posed by them. It is now known that
many of the risk factors such as smoking,
hypertension, dyslipidaemia, diabetes, physical inactivity and obesity are potentially
modiﬁable by health counselling.3 Available
evidence suggests that absolute CVD risk
assessment on the basis of the combined
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effect of multiple risk factors yields a greater degree of
accuracy than estimates based on individual risk
factors.4 5 Moreover, existing evidence also indicates that
the cost-effectiveness of management and treatment
decisions, including the use of medicine, should be
based on absolute CVD risk assessment.6
Most of the existing CVD risk-proﬁling packages rely
on equations based on Framingham and other similar
studies (eg, PROCAM (Munster), Seven Countries Study,
SCORE and Progetto CUORE studies).7–9 There is
limited evidence of the applicability of these protocols
in the context of developing countries, whose populations were not included in any of the aforementioned
study samples. In 2000, after consultation with experts in
all the WHO regions, the WHO released a risk-proﬁling
tool tailored to developing countries that aimed to facilitate systematic case management at all healthcare levels.
In 2007, this tool provided the framework for sets of
regional risk prediction charts developed by the WHO
and the International Society of Hypertension (WHO/
ISH). These were based on risk factors that could be
assessed by physician and non-physician health workers
in a primary care setting in each of the 14 WHO subregions.10 In recognition of resource limitations of LMICs,
these tools placed a low emphasis on laboratory investigations11 and aimed to guide the allocation of limited
healthcare resources in the most cost-effective way
among high-risk groups.10 Although the CVD risk scores
were originally intended for a quick, consistent measure
of absolute risk in individuals, through cross-sectional
surveys of population samples, they could also provide a
tool for estimating and monitoring population trends of
CVD risks.12 13
Bangladesh is an LMIC where the emerging
challenge in the health sector is non-communicable
diseases (NCDs) and, among all NCDs, the foremost
cause of death and disability is CVDs.2 14
Approximately 13.4% of disability adjusted life years
(DALYs) lost in Bangladesh are due to CVDs.15 These
problems are exacerbated, especially in primary healthcare sectors, by socioeconomic obstacles, non-uniform
accessibility to treatment, insufﬁcient stafﬁng of healthcare facilities and limited capacity for ancillary
investigations.
Few LMICs currently have clinical guidelines either
for screening or treatment of risk factors based on ‘absolute’ CVD risk scores, or any sort of estimate on the
population distribution of CVD risks over time. In
Bangladesh, studies aimed at risk estimation for CVDs
are still limited in number and even those which have
been conducted have mostly used an individual rather
than multiple risk factor approach. Cravedi et al16 have
conducted the only such study among urban and rural
populations. However the rural population in this study
was recruited from regions close to urbanised areas, so it
may not represent the risk factor pattern in more
remote rural populations. The present study was undertaken to assess the distribution of absolute CVD risk in a
2

remote rurali adult population, with and without cholesterol, using the WHO/ISH risk prediction charts and to
compare the concordance between the two approaches
with the tool including cholesterol treated as the gold
standard. We also compared the projected drug requirements for CVD prevention based on each version of the
assessment tool at risk thresholds of ≥20% and ≥30 for
single risk factors in order to assess applicability of the
tool in an LMIC setting.

METHODS
The selection of participants for the study has been
described previously.17 Brieﬂy, a prospective cohort of
(190 471) residents in a rural area of Bangladesh was
established in 2008 as part of the ‘BADAS-ORBIS Eye
Care Project’. The main objective was designed to generate epidemiological data on the burden of diabetic retinopathy and associated risk factors. In 2011–2012,
participants in the eye project cohort who had been
aged between 31 and 74 in 2008 were invited to participate in the North Bengal Non-Communicable Disease
Programme (NB-NCDP) of Bangladesh University of
Health Sciences (BUHS). Of 66 701 eligible residents,
63 708 consented ( participation rate 95.5%) and were
screened for CVDs using the ‘WHO CVD-RISK
Management Package for low and medium resource settings’.11 This questionnaire identiﬁed individuals at high
risk of a CVD event on the basis of current symptoms or
a history of pre-existing CVD. The screening process
identiﬁed 1170 individuals as high risk,11 who were then
immediately referred to the next level care, following
the WHO package guidelines. Among the 62 538
remaining cohort members, 1000 participants were randomly selected with the expectation that in the future,
after a 50% loss to follow-up, we would have sufﬁcient
participants to observe an association, as per a case
cohort design. Of the 1000 people invited, 563 (56.3%)
were willing to participate. The participants of this subcohort were checked for age, sex and education status
with the main cohort and did not observe any signiﬁcant
difference between participants and non-participants.
Using a structured, pretested interviewer-administrated
questionnaire, information was collected on the following: sociodemographic and economic characteristics, a
3-day dietary intake history (including fruit and vegetable
intake), current tobacco use (including type of smoking or
non-smoked tobacco use), smoking history, passive smoking,
alcohol intake (including local form of alcoholic beverages),
physical activity (assessed by exact daily duration (minutes) of
work-related, commute-related and leisure time-related physical
activity) and history of medicine intake for any chronic
disease. A health examination collected anthropometric
i

Most of the existing research conducted in Bangladeshi rural settings
has been in rural areas adjacent to urban spaces, whereas a remote
rural area is one geographically and behaviourally distinct from urban
inﬂuences
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measurements (ie, height, weight, waist and hip circumferences), blood pressure measurements ((BP), measured 3
times in sitting position), fasting and 2 hBG (2 h blood
glucose after having 75 g oral glucose for the oral glucose tolerance test) and blood sample collection for biochemical
measurements (ie, lipid proﬁle). Whole capillary blood
was taken and centrifuged serum was separated and
refrigerated for analysis. Plasma glucose was measured
by the glucose oxidase method using DimalesionRxL
Max (Siemens AG, Erlangen, Germany) and plasma–TC
was analysed by the enzymatic colorimetric method.
Verbal consent in the presence of a witness was obtained
for all participants.
Calculating absolute CVD risk using the WHO/ISH risk
prediction charts
To classify absolute CVD risk, individuals were evaluated
using the WHO/ISH risk assessment charts for the
South-East Asian Region: D. The WHO and ISH have
devised two sets of risk prediction charts—with and
without blood cholesterol.11 18 Both sets require data on
sex (male/female), age in years (31–49, 50–59, 60–69 and
≥70 years), systolic blood pressure (<140 mm Hg; 140–
160 mm Hg, 160–180 mm Hg and ≥180 mm Hg, the mean of
the last two of the three measurements taken in rested participants in sitting position), smoking status (no, yes,
ex-smoker<12 months), presence or absence of diabetes
status (yes/no, deﬁned by fasting blood glucose ≥7 mmol/L)
and record of oral hypoglycaemic drug use if blood
sugar is measured below these threshold levels, in order
to estimate risk of a cardiovascular event in the next
10 years. The chart developed for settings where blood
cholesterol can be measured also uses blood cholesterol
(total cholesterol in ﬁve categories: <5 mmol/L, 5–<6 mmol/L,
6–<7 mmol/L, 7–<8 mmol/L and ≥8 mmol/L). The charts
provide evidence-based recommendations on the initiation of speciﬁc preventive actions (behavioural or
pharmacological) and their intensity. In this study, we
categorised the population according to the risk of
developing a fatal or non-fatal severe CVD event (acute
myocardial infarction and/or stroke) in the next 10 years
into four levels: low, <10%; moderate, 10–19.9%; high,
20–29.9%; and very high risk, ≥30%.18 19 The WHO criteria and recommendations as well as expert consensus
recommend drug therapy to prevent CVD in people
with a CVD risk threshold ≥30%, or ≥20% if ﬁnancially
feasible.10 19–21
Statistical methods
Analysis was conducted using Stata V.12 (StataCorp LP,
College Station, Texas, USA). Percentages with 95% CIs
were calculated for categorical variables. Means, SDs and
95% CIs were calculated for continuous variables. Excel
ﬁle 2003 (Microsoft) was used for CVD risk calculation,
data entry and processing. For CVD risk prediction analysis, we used the method described in the WHO guidelines.10 We used the χ2 test for statistical signiﬁcance
with a threshold of p<0.05. For data analysis, we used the
Fatema K, et al. BMJ Open 2015;5:e008140. doi:10.1136/bmjopen-2015-008140

method described in the WHO guidelines.22
Concordance between the two prediction charts was calculated for the different risk levels assuming the chart
with cholesterol as the reference (ie, if CVD risk was classiﬁed higher without cholesterol, we described it as an
overestimate; if lower, as an underestimate). Cohen’s κ
was used to observe the inter-rater agreement between
with and without cholesterol for a 10 year CVD risk
score.
RESULTS
Overview of the risk burden among study participants
After analysis, the overall demographic and social
characteristics of all the study participants showed that
male representation was higher (66.1%), about threequarters of the participants (73%) had low or poor educational knowledge (ie, illiterate/only signature/
gonoshikha and primary education) and almost 99%
were from the low and lower middle-income group and
67.1% of them were from the physically active group (ie,
homemaker /farmer) (data not shown on a table).
Distribution of individual risk factors used in absolute
CVD-risk assessment
Among the 563 participants (aged 31–74 years), mean
ages were 51.9±10.6 versus 47.7±10.8 years for males
versus females, respectively. Among CVD risk factors,
prevalence of smoking was the highest (75.8%), followed
by systolic blood pressure ≥140 mm Hg (9.1%), fasting
blood glucose ≥7 mmol/L (2.7%) and fasting blood
cholesterol ≥6 mmol/L (18.1%). The trends by age and
sex should be noted as the WHO/ISH charts include
both of these demographic characteristics as the key
deﬁning variables in the risk charts (table 1).
Distribution of ‘absolute’ CVD risk using the WHO/ISH risk
prediction charts alone
The distribution of absolute CVD risk using both sets
(with and without cholesterol) is shown in table 2.
When risk assessment was performed with cholesterol,
89% had a 10-year CVD risk of <20%; the corresponding
proportion was 92.2% when cholesterol was not
included in the calculation. The proportions with risk
≥20% (high and very high) were 11% with cholesterol
versus 7.8% without. When we applied the charts
without cholesterol, the percentage of the population in
the high (20–29.9% 10-year risk) and very high-risk categories (≥30% 10-year risk) was less than with the chart
using cholesterol (4.3 vs 5.3 and 3.6 vs 5.7, respectively),
but the difference was not statistically signiﬁcant. In
general, males had a higher risk of CVD according to
both the tools.
Concordance of the two CVD risk charts
In this study, concordance was found between the two
charts for 504 (89.5%) participants (table 3). Using the
with cholesterol version as the gold standard, the chart
3
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Table 1 Gender and age distribution and the prevalence of CVD risk factors of the study participants (n=563)
Age group (years)
31–49
50–59
Gender
Male
Female
Total n (%)
Variables
*HTN
†DM
‡HC
Smoking

≥70

60–69

152 (40.9)
116 (31.2)
74 (19.9)
30 (8.1)
110 (57.6)
47 (24.6)
23 (12.0)
11 (5.8)
262 (46.5)
163 (29.0)
97 (17.2)
41 (7.3)
Prevalence of CVD risk factors % (95% CI)
5.3 (3.0 to 8.8)
6.7 (3.4 to 11.8) 20.6 (13.1 to 30.0) 14.6 (5.6 to 29.2)
2.0 (0.6 to 4.4)
1.8 (0.4 to 5.3)
5.2 (1.7 to 11.6)
2.7 (0.6 to 12.9)
15.3 (11.1 to 20.2) 22.7 (16.5 to 29.9) 22.7 (14.8 to 32.3) 7.3 (1.5 to 19.9)
68.7 (62.7 to 74.3) 79.8 (72.8 to 85.6) 84.5 (75.8 to 91.1) 85.4 (70.8 to 94.4)

Total n (%)

Mean±SD

372 (66.1)
191 (33.9)
563 (100)

51.9±10.6
47.7±10.8
50.5±10.9

9.1 (6.8 to 11.7)
2.7 (1.5 to 4.3)
18.1 (15.0 to 21.6)
75.8 (72.1 to 79.3)

–
–
–
–

*HTN (ie, SBP ≥140 mm Hg).
†DM (ie, fasting blood glucose ≥7.0 mmol/L).
‡HC (ie, fasting blood cholesterol ≥6.0 mmol/L).
CVD, cardiovascular disease; DM, diabetes mellitus HC, high cholesterol; HTN, hypertension.

without cholesterol overestimated CVD risk in 43 (7.6%)
participants and underestimated risk in 16 (2.8%) participants. Of the 59 individuals with non-concordant CVD
risk estimates, 72.8% (43/59) were overestimated (29/41
men and 14/18 women); 40.7% (24/59) belonged to
low and moderate CVD risk categories that would not
have drug intervention at a CVD threshold risk of ≥20%
with either chart. Only 4.3% (24/563) of the total
sample was misclassiﬁed vice versa need for drug intervention: risk was overestimated in 3.4% (19/563) and
underestimated in 1.1% (6/563).

drug treatment (10.1% antihypertensives and 18.1%
lipid-lowering drugs); almost ﬁvefold higher than
without cholesterol and sevenfold higher than with the
cholesterol risk approach (table 4).

DISCUSSION
Data from this study show that about 10% of the adult
populations, even in a peripherally located rural population of Bangladesh, are at high risk of a CVD event in
the next 10 years and half of these individuals are in the
very high-risk category. These proportions are similar
whether the ‘with or without’ cholesterol version of the
WHO/ISH CVD Risk-Assessment Tool is used. The risk
is in terms of a 10-year absolute CVD Risk, which is
much higher than that recently reported by Cravedi
et al,16 using only the without cholesterol version of the
tool, in another rural Bangladeshi population. In that
study, the proportion of higher risk participants is only
2.1% (very high risk 1.2% and high risk 0.9%), whereas
in this study, using the same tool, the corresponding
proportion is 7.9% (very high risk 3.6% and high risk
4.3%). The reasons for these discrepancies are not presently known; however, population differences related to

Comparison of drug requirement among study participants
Using the WHO guidelines for CVD risk assessment and
management, (2) estimates of proportions of persons
requiring medications to reduce CVD risk in this sample
were similar by both with and without cholesterol charts.
Using a threshold of ≥30% 10-year risk, 6.1% of those
studied without measuring cholesterol were classiﬁed as
requiring drugs, 4.1% of those studied were those in
whom cholesterol was measured. Using a threshold of
≥20%, the proportions were 11.4% and 8.4%, respectively. Applying the single-risk-factor approach, about
28.2% (159 of 563) of the participants would require

Table 2 Ten-year absolute CVD risk prediction by gender, using the WHO/ISH SAER D charts, with and without cholesterol
WHO/ISH SAER
D chart
With cholesterol

Without cholesterol

Gender

10-Year WHO/ISH cardiovascular risk prediction
Low risk (<10) Moderate risk (10–19.9) High risk (20–29.9)

Very high risk (30–39.9)

Male
Female
Total
Male
Female
Total

77.7
80.1
78.5
78.5
82.7
79.9

5.1
6.8
5.7
2.7
5.2
3.6

(289/372)
(153/191)
(442/563)*
(292/372)
(158/191)
(450/563)*

11.3
8.9
10.5
13.2
10.5
12.3

(42/372)
(17/191)
(59/563)†
(49/372)
(20/191)
(69/563)†

5.9
4.2
5.3
5.6
1.6
4.3

(22/372)
(8/191)
(30/563)‡
(21/372)
(3/191)
(24/563)‡

(19/372)
(13/191)
(32/563)§
(10/372)
(10/191)
(20/563)§

*χ2=0.35 p=0.557.
†χ2=0.88 p=0.348.
‡χ2=0.70 p=0.403.
§χ2=2.90 p<0.088.
CVD, cardiovascular disease, WHO/ISH, WHO/ International Society of Hypertension.
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Table 3 Concordance of the WHO/ISH SAER D CVD risk charts with and without cholesterol for participants
CVD risk
With cholesterol

Without cholesterol N (%) for participants
Low risk (<10) Moderate risk (10–19.9) High risk (20–29.9)

Very high risk (30–39.9)

Total (%)

Low risk
Moderate risk
High risk
Very high risk
Total (%)

432 (76.7)
10 (1.8)
0
0
442 (78.5)

1 (0.2)
7 (1.2)
7 (1.2)
17 (3.0)
32 (5.7)

450 (79.9)
69 (12.3)
24 (4.3)
20 (3.6)
563 (100.0)

12
41
3
3
59

(2.1)
(7.3)
(0.5)
(0.5)
(10.5)

5
11
14
0
30

(0.9)
(2.0)
(2.5)
(5.3)

Concordance: 89.5% (504/563).
Non-concordance: 10.5% (59/563).
Overestimate: 7.6% (43/563).
Underestimate: 2.8% (16/563).
Misclassification for CVD risk threshold ≥20%: 4.3% (24/563).
Overestimate: 3.4% (19/563).
Underestimate: 1.1% (6/563).
κ Value (0.705, p<0.001).
CVD, cardiovascular disease, WHO/ISH, WHO/International Society of Hypertension.

genetic as well as environmental, sociodemographic and
lifestyle factors may contribute to the wide difference in
the prevalence of the higher risk of CVDs among the
two groups. It needs to be noted that the proportion of
the 10-year absolute CVD risk positive (higher than the
low risk group including the moderate CVD risk group)
participants (25% in the Cravedi study vs 20.2% in this
study) are fairly similar in the two studies.
With the exception of the work as cited above, no
other study has reported absolute CVD risk among the
Bangladeshi population (using the WHO/ISH Tool or
any other absolute risk scoring system). The without
cholesterol version of the tool was applied in various
other countries; a similar proportion of risk positive
(moderate, high and very high) groups has been
reported from Bolivia (11.3%) and higher proportions
have been reported from Nepal (16.9%), the USA

(18.2%) and Georgia (25%).12 Comparative data using
‘with cholesterol’ shows considerable similarity with our
ﬁndings (78.5%) for low risk (<10%) group in Pakistan,
Georgia, Nepal, Nigeria, Mongolia and Cuba (79.2%,
83.1%, 87.2%, 86%, 89.6% and 89.7% respectively); and
somewhat 10% higher in Iran, Sri Lanka, Malaysia,
China and Cambodia (93.9%, 94.9%, 94.4%, 96.1% and
97%, respectively). However, among the moderate or
high-risk groups, males show a higher preponderance in
almost all countries except Sri Lanka and Nepal, which
is similar to our ﬁndings.12 23 24
The major focus of this study was to ﬁnd out the level
of agreement between the results generated by the
without and with cholesterol versions of the WHO/ISH
Tool. From the frequency distribution (table 2), it can be
seen that the results from the two versions do not differ
signiﬁcantly when both genders are considered as a

Table 4 Association of drug requirements for CVD prevention among the study population as per total CVD risk
assessment, with and without cholesterol, and single risk factor line

Approaches

Variants

Participants (n=563)
Persons requiring drugs
Threshold ≥30%
Threshold ≥20%
No.
%
No.
%

Total CVD risk without cholesterol

Elevated risk per charts alone
Charts normal with BP ≥160/100
Total
Elevated risk per charts alone
Charts normal with BP ≥160/100
Charts normal with TC ≥8
Total
BP ≥140/90
TC ≥6
Total

32
2
34*
20
2
1
23§
57*
102
159§

Total CVD risk with cholesterol

Single risk factor

5.7
0.36
6.06†
3.55
0.36
0.18
4.09¶
10.1
18.1
28.2

62
2
64‡
44
2
1
47**
57‡
102
159**

11.07
0.36
11.43†
7.82
0.36
0.18
8.35¶
10.1
18.1
28.2

*Without cholesterol versus single risk factor, threshold ≥30%: χ2=6.32, p<0.012.
†Without cholesterol, threshold ≥30% versus without cholesterol, threshold ≥20%: χ2=10.06, p<0.002.
‡Without cholesterol versus single risk factor, threshold ≥20%: χ2=0.45, p<0.500.
§ With cholesterol versus single risk factor, threshold ≥30%: χ2=123.9, p<0.001.
¶With cholesterol, threshold ≥30% versus with cholesterol, threshold ≥20%: χ2=8.77, p<0.003.
**With cholesterol versus single risk factor, threshold ≥20%: χ2=74.5, p<0.001.
BP, blood pressure; CVD, cardiovascular disease; TC, total cholesterol.
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combined group. However, when males and females are
analysed separately, wide discrepancies are found in the
results of the two charts. There is a gross chance of overestimation (by about 71%) of very high risk among males
and (by about 78%) of high risk among females in using
without cholesterol compared with the cholesterol
version. Similarly, when the concordance between the
two versions was statistically tested, the agreement
between the two versions was fair (89.5%) considering
the subject group as a whole. However, repeating the tests
separately in males and females resulted in similar levels
of concordance (89% and 90.6%, respectively). On the
basis of the overall population, the concordance rate in
this study is similar to that in a Cuban study,23 but it is
higher than that in a study which applied a Framingham
CVD risk score using cholesterol and/or BMI formulae.25
In this study, the agreement was further explored by
an empirical technique using the need for medication
as suggested by the two versions of the WHO/ISH Tool.
It can be seen that, compared to the single factor risk
assessment approach, a much less proportion of participants require drug treatment when they are scored by
the WHO/ISH Tool. However, this percentage of the
population is about ﬁvefold to sevenfold higher
(whether the threshold of the absolute risk is >30% or
>20%) when suggestion is generated by the with cholesterol version compared to the without cholesterol
version of the Tool. It thus appears that the reduction of
the CVD risk threshold from ≥30% to ≥20% greatly
improves the diagnosis of patients and did not introduce
overprescription of drugs. However, both tools assessed
better targeting of those more likely to develop CVD
and, compare with the single-risk-factor approach, still
showed either an underestimate or less need for drugs
in a substantial proportion of participants. There is still
no universal consensus on the threshold level (>30% vs
20%) that is required to make a decision for drug treatment12 23 and the question may still be raised whether
the absolute risk factor approaches may introduce
undertreatment. The WHO proposes that the CVD risk
threshold for intensive intervention across a 10-year
span should be based on the resource levels of respective countries.23 Moreover, with or without cholesterol
guidelines are not compared to any gold standard, that
is, the WHO risk score (for region) is based on the modelling of various data from different countries but not
on real data in Bangladesh (ie, there are no cohort
studies in Bangladesh or neighbouring countries providing actual prospective CVD outcome data in relation to
risk factors in these countries). Therefore, it is obvious
that much of the data, particularly those based on longitudinal studies, need to be generated in Bangladesh to
initiate more evidence-based discussion in this ﬁeld.
In conclusion, about one-ﬁfth of the adult people in
Bangladesh, even in a remote rural area, seem to be at
risk of developing CVDs within 10 years. Among this,
one-ﬁfth, about 25%, are at high risk and another 25%
are at very high risk of developing the disorders with
6

males and females being almost equally vulnerable. Our
data indicate that use of the with cholesterol version of
the WHO/ISH 10-year absolute CVDs risk assessment
could avoid overestimation of the risk, particularly in the
high-risk and very high-risk subgroups, and undertreatment of participants who should be treated with medication. On the other hand, a very high concordance
between the with and without cholesterol tools indicates
that with the resource limitations and less facilities for
laboratory investigations settings, the without cholesterol
tools allow for better targeting of those who are more
likely to develop cardiovascular diseases. The ﬁnding
also indicates that a large-scale study could be conducted to verify the pattern.
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